Introduction
Please use this section of the site to find useful information and content
European Commission
April 2013
What you need to know about Biosimilar Medicinal Products
- A Consensus Information Document
Please click here to view.
December 2015
IMS study: Impact of Biosimilar Competition
Please click here to read the full report.
Please click here to view the reading guide.
Please click here to read the five observations by IMS.
January 2017
European Commission Q&A for patients - Biosimilar medicines explained
Please click here to view
May 2017
QuintilesIMS -The Impact of Biosimilar Competition in Europe, Update
Please click here to view
December 2017
European Commission launches "What I need to know about Biosimilar Medicines - Information for patients" in 23 EU languages
Please click here to view
European Medicines Agency
Scientific guidelines on biosimilar medicines
Please click here to view the whole range of documents.
Biosimilar medicines approved by the EMA
Please click here to view
Biosimilars in the EU - information guide to healthcare professionals
Please click here to view
IMS data
March 2016
Delivering on the Potential of Biosimilar Medicines
The Role of Functioning Competitive Markets, March 2016
Please click here to view
Medicines for Europe
Factors supporting a sustainable European biosimilars medicines market
- GfK report
Please click here to view.
FAMHP position on biosimilar medicines
Please click here to view the Belgian medicines agency position
The Nor-Switch study: More real world evidence of physician led switching to biosimilar medicines
Please click here for further details
European Commission Question & Answer Document for Patients Builds Trust and Understanding on Biosimilar Medicines across Europe
Please click here for further details
European Commission Initiative improves information for patients on biosimilar medicines
Please click here for futher details
Medicines Optimisation
January 2017
The Medicines Optimisation Hospital Trust Dashboard is hosted on NHS England’s website, please click here to view.
MHRA
Drug safety update – biosimilar product
Please click here to view.
NHS England
April 2017
Cancer Vanguard
Please click here to view.
September 2015
What is a biosimilar medicine?
Please click here to view.
NICE
May 2010
Human growth hormone (somatropin) for the treatment of growth failure in children
Please click here to view.
November 2014
Erythropoiesis stimulating agents (epoetin and darbepoetin) for treating anaemia in people with cancer having chemotherapy
Please click here to view.
January 2015
NICE position paper on biosimilar medicines
Please click here to view.
February 2015
Infliximab, adalimumab and golimumab for treating moderately to severely active ulcerative colitis after the failure of conventional therapy
Please click here to view.
July 2015
Introducing biosimilar versions of infliximab: Inflectra and Remsima
Please click here to view.
January 2016
Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed
Please click here to view.
February 2016
Medicines optimisation: Key therapeutic topics
Please click here to view.
Professional Groups
BSG guidance on the use of biosimilar Infliximab CT-P13 in IBD, February 2016
Please click here to view.
RCP - UK IBD audit highlights potential huge cost savings of using new biosimilar medicines, September 2016
Please click here to view
BOPA Guidelines - Implementation of Biosimilar MABs in Oncology, Role of Pharmacy, February 2017
Please click here to view